Addition of History of Intussusception as a Contraindication for Rotavirus Vaccination
The Food and Drug Administration (FDA) has approved revised prescribing information and patient labeling from GlaxoSmithKline Biologicals for the monovalent rotavirus vaccine (RV1, marketed as Rotarix) and revised prescribing information and patient labeling from Merck & Co. for the pentavalent rotavirus vaccine (RV5, marketed as RotaTeq) to include history of intussusception as a contraindication (1,2). FDA approved the revisions for RV1 in February 2011 and for RV5 in July 2011. In its rotavirus vaccination recommendations, CDC is updating the contraindications for rotavirus vaccine (RV1 and RV5) to include history of intussusception. Previously, CDC had considered history of intussusception a precaution but not a contraindication (3,4).
Intussusception is a telescoping of one portion of the intestine into another, which can result in bowel obstruction and subsequent bowel ischemia. Intussusception is treated in the hospital setting with a specialized enema or a surgical procedure. Before rotavirus vaccine was used, about 1,900 infants developed intussusception each year in the United States. Some, but not all, postmarketing studies of the currently licensed vaccines have detected an increased risk for intussusception following rotavirus vaccine administration, particularly during the first week following the first dose of vaccine. More information on the possible risk for intussusception in U.S. infants following rotavirus vaccination is available on CDC and FDA websites (5--8). If the risk exists, rotavirus vaccination could cause about 50--60 additional intussusception cases in the United States each year while preventing more than 50,000 hospitalizations each year from rotavirus disease.
Compared with infants who have never had intussusception, infants with a history of intussusception are at greater risk for intussusception. According to case series reports on intussusception (infants and young children combined), approximately 5%--10% of patients with intussusception have a subsequent episode (9). Specific data, however, are not available on the risk for a subsequent episode of intussusception following rotavirus vaccination of infants with a history of intussusception.
CDC is updating its contraindications for rotavirus vaccine (3,10). Rotavirus vaccination is now contraindicated for 1) infants with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of rotavirus vaccine or exposure to a vaccine component, 2) infants diagnosed with severe combined immunodeficiency (SCID), and 3) infants with a history of intussusception.
- Food and Drug Administration. Product-approval information-licensing action [package insert]. Rotarix (rotavirus vaccine, live, oral), GlaxoSmithKline Biologicals. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm133539.pdf. Accessed October 17, 2011.
- Food and Drug Administration. Product-approval information-licensing action [package insert] RotaTeq (rotavirus vaccine, live, oral, pentavalent), Merck & Co. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2011. Available at http://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm142288.pdf. Accessed October 17, 2011.
- CDC. Prevention of rotavirus gastroenteritis among infants and children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2009;58(No. RR-2).
- Cortese M. Estimates of benefits and potential risks of rotavirus vaccination in the United States. Presented at the meeting of the Advisory Committee on Immunization Practices, Atlanta, GA; October 28, 2010. Available at http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-oct10/12-3-rota-estbenefitsrisks.pdf. Accessed October 17, 2011.
- CDC. Statement regarding Rotarix and RotaTeq rotavirus vaccines and intussusception. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/vpd-vac/rotavirus/intussusception-studies-acip.htm. Accessed October 17, 2011.
- CDC. Monitoring of intussusception after RotaTeq vaccination 2011. Atlanta, GA: US Department of Health and Human Services, CDC; 2011. Available at http://www.cdc.gov/vaccinesafety/vaccines/rotateq_intussusception.html. Accessed October 17, 2011.
- CDC. Updated vaccine label for Rotarix: questions and answers for health-care professionals. Atlanta, GA: US Department of Health and Human Services, CDC; 2010. Available at http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-label-hcp.htm. Accessed October 17, 2011.
- Food and Drug Administration. Information on Rotarix---labeling revision pertaining to intussusception. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2010. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm226690.htm. Accessed October 17, 2011.
- Daneman A, Alton DJ, Lobo E, Gravett J, Kim P, Ein SH. Patterns of recurrence of intussusception in children: a 17-year review. Pediatr Radiol 1998;28:913--9.
- CDC. Addition of severe combined immunodeficiency as a contraindication for administration of rotavirus vaccine. MMWR 2010;59:687--8.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to email@example.com.